Brand Name(s): Rituxan; Mabthera
CAS nº: 174722-31-7
(rih tux ih mab)
About Rituximab
This site is dedicated exclusively to rituximab.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about rituximab on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total rituximab experience!
Why is this medication prescribed?
Rituximab is a cancer (antineoplastic) medication. It works by interfering with the growth of cancer cells by slowing their growth and spread in the body.
Rituximab is also used in the treatment of non-Hodgkin's lymphoma.
Additionally, this medication can be used alone or in combination with other chemotherapeutic drugs. Specifically, very good results have been seen when used in combination with the CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone).
Rituximab is sold as Rituxan® in the United States.
Latest News
Cancer Drug Slows Multiple Sclerosis Progression
Two shots of the cancer drug Rituxan given two weeks apart slowed the progression of multiple...
[more]Role of Mitoxantrone in Combination Therapy for Chronic Lymphocytic Leukemia (CLL) Evaluated
Researchers from Spain have reported preliminary results of initial treatment of patients with...
[more]Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical...
[more]MabThera(REG) Helps Patients With Lymphoma Stay Symptom Free And Live Longer
A study published recently in Blood, the journal of the American Society of Hematology, has...
[more]FDA Issues Safety Warning On Biogen Drug; Stock Is Falling
Monday, the U.S. Food and Drug Administration or FDA issued a warning to healthcare professionals...
[more]